These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32394440)

  • 1. Recent strategies for the development of oral medicines for the treatment of visceral leishmaniasis.
    de Souza ML; Gonzaga da Costa LA; Silva EO; de Sousa ALMD; Dos Santos WM; Rolim Neto PJ
    Drug Dev Res; 2020 Nov; 81(7):803-814. PubMed ID: 32394440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous leishmaniasis: new oral therapeutic approaches under development.
    de Souza ML; Dos Santos WM; de Sousa ALMD; Ferraz LRM; da Costa LAG; Silva EO; Rolim Neto PJ
    Int J Dermatol; 2022 Jan; 61(1):89-98. PubMed ID: 34510406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
    Singh S ; Kumar J; Singh R; Dwivedi SN
    Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kala-azar--progress against a neglected disease.
    Murray HW
    N Engl J Med; 2002 Nov; 347(22):1793-4. PubMed ID: 12456856
    [No Abstract]   [Full Text] [Related]  

  • 8. Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report.
    Mbui J; Rashid R; Lodenyo H; Nyakundi P; Kipmutai R; Mutuma G; Kirigi G; Kinoti D; Wasunna M
    East Afr Med J; 2003 Aug; 80(8):440-2. PubMed ID: 14601788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
    Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE
    Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829
    [TBL] [